Elena Lucertini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Elena Lucertini has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Laghi
Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Department of Diagnostic Imaging, via Manzoni 56, 20089 Rozzano, Milan, Italy; Department of Surgery, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, the Netherlands
8 shared publications - Damiano Caruso
Radiology Unit, Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, Sant’Andrea Hospital, 00189 Rome, Italy
7 shared publications - Marta Zerunian
Radiology Unit, Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, Sant’Andrea Hospital, 00189 Rome, Italy
7 shared publications - Michela Polici
Radiology Unit, Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, Sant’Andrea Hospital, 00189 Rome, Italy
6 shared publications - Tiziano Polidori
Radiology Unit, Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, Sant’Andrea Hospital, 00189 Rome, Italy
6 shared publications - Francesco Pucciarelli
Radiology Unit, Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, Sant’Andrea Hospital, 00189 Rome, Italy
4 shared publications
Latest Publications
- 9 August 2022
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 45 (9) , 1385-1390
Present Status of Thyroid Ablation in Europe: An International Survey among the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Members
Aim To evaluate the effective spread of image-guided thermal ablation in thyroid gland and to characterize its current perceptions among European interventional radiologists. Materials and methods A questionnaire with 29 multiple choice questions about thyroid ablation was sent as an E-blast to 4752 CIRSE members. Only those who completed the survey in all its parts were included in the study. Results 242/4752 (5.09%) participants (212 males and 30 females) completed and submitted the survey. A total of 160 subjects (66.1%) were familiar with any image-guided thermal ablations, but only 63 (26% of total population) usually perform thermal ablation for thyroid gland. Only 19.5% of the interviewed sample treats micropapillary thyroid tumours and the vast majority routinely uses radiofrequency ablation (84.4%). Conclusion There is a significant mismatch between thyroid ablation as reported by the literature and the relatively low percentage of interventional radiology actively performing such procedure in Europe. A considerable effort is required by the Cardiovascular and Interventional Radiological Society of Europe to fill this lack.
- 9 August 2022
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 45 (9) , 1385-1390
Present Status of Thyroid Ablation in Europe: An International Survey among the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Members
Aim To evaluate the effective spread of image-guided thermal ablation in thyroid gland and to characterize its current perceptions among European interventional radiologists. Materials and methods A questionnaire with 29 multiple choice questions about thyroid ablation was sent as an E-blast to 4752 CIRSE members. Only those who completed the survey in all its parts were included in the study. Results 242/4752 (5.09%) participants (212 males and 30 females) completed and submitted the survey. A total of 160 subjects (66.1%) were familiar with any image-guided thermal ablations, but only 63 (26% of total population) usually perform thermal ablation for thyroid gland. Only 19.5% of the interviewed sample treats micropapillary thyroid tumours and the vast majority routinely uses radiofrequency ablation (84.4%). Conclusion There is a significant mismatch between thyroid ablation as reported by the literature and the relatively low percentage of interventional radiology actively performing such procedure in Europe. A considerable effort is required by the Cardiovascular and Interventional Radiological Society of Europe to fill this lack.
- Top Cited Papers
- 1 November 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 301 (2) , E396-E405
Post-Acute Sequelae of COVID-19 Pneumonia: Six-month Chest CT Follow-up
At 6-month follow-up chest CT, COVID-19 postacute sequelae were detected in 72% of patients: fibrotic-like changes were the most common residual findings (72%), followed by ground-glass opacities (... Background The long-term post acute pulmonary sequelae of COVID-19 remain unknown. Purpose To evaluate lung injury in patients affected by COVID-19 pneumonia at six-month follow-up compared to base...
- 1 November 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 301 (2) , E396-E405
Top Cited PapersPost-Acute Sequelae of COVID-19 Pneumonia: Six-month Chest CT Follow-up
At 6-month follow-up chest CT, COVID-19 postacute sequelae were detected in 72% of patients: fibrotic-like changes were the most common residual findings (72%), followed by ground-glass opacities (... Background The long-term post acute pulmonary sequelae of COVID-19 remain unknown. Purpose To evaluate lung injury in patients affected by COVID-19 pneumonia at six-month follow-up compared to base...
- Open Access
- 30 October 2021
- Published by Morressier GmbH
COVID-19 second epidemic wave: What is changed in HRCT?
Purpose: To compare CT signs of COVID-19 pneumonia between the two epidemic waves and verify if the incidence of COVID-19 pneumonia's advanced stages was less frequent in the second wave. Moreover, to evaluate if chest CT diagnostic accuracy and radiologists’ ability to identify COVID-19 pneumonia among other interstitial pulmonary pathologies was changed. Methods and
- 30 October 2021
- Published by Morressier GmbH
Open AccessCOVID-19 second epidemic wave: What is changed in HRCT?
Purpose: To compare CT signs of COVID-19 pneumonia between the two epidemic waves and verify if the incidence of COVID-19 pneumonia's advanced stages was less frequent in the second wave. Moreover, to evaluate if chest CT diagnostic accuracy and radiologists’ ability to identify COVID-19 pneumonia among other interstitial pulmonary pathologies was changed. Methods and
- 1 October 2021
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 76, 426-435
Aspiration Thrombectomy with the Indigo System for Acute Lower Limb Ischemia: Preliminary experience and analysis of parameters affecting the outcome
- 1 October 2021
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 76, 426-435
Aspiration Thrombectomy with the Indigo System for Acute Lower Limb Ischemia: Preliminary experience and analysis of parameters affecting the outcome
- 1 September 2021
- Published by Elsevier in European Journal of Radiology
- Vol. 142, 109874
Radiomics and functional imaging in lung cancer: the importance of radiological heterogeneity beyond FDG PET/CT and lung biopsy
- 1 September 2021
- Published by Elsevier in European Journal of Radiology
- Vol. 142, 109874
Radiomics and functional imaging in lung cancer: the importance of radiological heterogeneity beyond FDG PET/CT and lung biopsy
- Open Access
Radiomics in Oncology, Part 2: Thoracic, Genito-Urinary, Breast, Neurological, Hematologic and Musculoskeletal Applications
Radiomics has the potential to play a pivotal role in oncological translational imaging, particularly in cancer detection, prognosis prediction and response to therapy evaluation. To date, several studies established Radiomics as a useful tool in oncologic imaging, able to support clinicians in practicing evidence-based medicine, uniquely tailored to each patient and tumor. Mineable data, extracted from medical images could be combined with clinical and survival parameters to develop models useful for the clinicians in cancer patients’ assessment. As such, adding Radiomics to traditional subjective imaging may provide a quantitative and extensive cancer evaluation reflecting histologic architecture. In this Part II, we present an overview of radiomic applications in thoracic, genito-urinary, breast, neurological, hematologic and musculoskeletal oncologic applications.
Open AccessRadiomics in Oncology, Part 2: Thoracic, Genito-Urinary, Breast, Neurological, Hematologic and Musculoskeletal Applications
Radiomics has the potential to play a pivotal role in oncological translational imaging, particularly in cancer detection, prognosis prediction and response to therapy evaluation. To date, several studies established Radiomics as a useful tool in oncologic imaging, able to support clinicians in practicing evidence-based medicine, uniquely tailored to each patient and tumor. Mineable data, extracted from medical images could be combined with clinical and survival parameters to develop models useful for the clinicians in cancer patients’ assessment. As such, adding Radiomics to traditional subjective imaging may provide a quantitative and extensive cancer evaluation reflecting histologic architecture. In this Part II, we present an overview of radiomic applications in thoracic, genito-urinary, breast, neurological, hematologic and musculoskeletal oncologic applications.
- Open Access
- 26 May 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (6) , 956
Hepatocellular Carcinoma Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE): Outcome Analysis Using a Model Based On Pre-Treatment CT Texture Features
(1) Introduction and Aim: The aim of this study is to investigate the prognostic value, in terms of response and survival, of CT-based radiomics features for patients with HCC undergoing drug-eluting beads transarterial chemoembolization (DEB-TACE). (2) Materials and Methods: Pre-treatment CT examinations of 50 patients with HCC, treated with DEB-TACE were manually segmented to obtain the tumor volumetric region of interest, extracting radiomics features with TexRAD. Response to therapy evaluation was performed basing on post-procedural CT examination compared to pre-procedural CT, using modified RECIST criteria for HCC. The prognostic value of texture analysis was evaluated, investigating the correlation between radiomics features, response to therapy and overall survival. Three models based on texture and clinical variables and a combination of them were finally built; (3) Results: Entropy, skewness, MPP and kurtosis showed a significant correlation with complete response (CR) to TACE (all p < 0.001). A predictive model to identify patients with a high and low probability of CR was evaluated with an ROC curve, with an AUC of 0.733 (p < 0.001). The three models built for survival prediction yielded an HR of 2.19 (95% CI: 2.03–2.35) using texture features, of 1.7 (95% CI: 1.54–1.9) using clinical data and of 4.61 (95% CI: 4.24–5.01) combining both radiomics and clinical data (all p < 0.0001). (4) Conclusion: Texture analysis based on pre-treatment CT examination is associated with response to therapy and survival in patients with HCC undergoing DEB-TACE, especially if combined with clinical data.
- 26 May 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (6) , 956
Open AccessHepatocellular Carcinoma Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE): Outcome Analysis Using a Model Based On Pre-Treatment CT Texture Features
(1) Introduction and Aim: The aim of this study is to investigate the prognostic value, in terms of response and survival, of CT-based radiomics features for patients with HCC undergoing drug-eluting beads transarterial chemoembolization (DEB-TACE). (2) Materials and Methods: Pre-treatment CT examinations of 50 patients with HCC, treated with DEB-TACE were manually segmented to obtain the tumor volumetric region of interest, extracting radiomics features with TexRAD. Response to therapy evaluation was performed basing on post-procedural CT examination compared to pre-procedural CT, using modified RECIST criteria for HCC. The prognostic value of texture analysis was evaluated, investigating the correlation between radiomics features, response to therapy and overall survival. Three models based on texture and clinical variables and a combination of them were finally built; (3) Results: Entropy, skewness, MPP and kurtosis showed a significant correlation with complete response (CR) to TACE (all p < 0.001). A predictive model to identify patients with a high and low probability of CR was evaluated with an ROC curve, with an AUC of 0.733 (p < 0.001). The three models built for survival prediction yielded an HR of 2.19 (95% CI: 2.03–2.35) using texture features, of 1.7 (95% CI: 1.54–1.9) using clinical data and of 4.61 (95% CI: 4.24–5.01) combining both radiomics and clinical data (all p < 0.0001). (4) Conclusion: Texture analysis based on pre-treatment CT examination is associated with response to therapy and survival in patients with HCC undergoing DEB-TACE, especially if combined with clinical data.
- Open Access
Radiomics in Oncology, Part 1: Technical Principles and Gastrointestinal Application in CT and MRI
Radiomics has been playing a pivotal role in oncological translational imaging, particularly in cancer diagnosis, prediction prognosis, and therapy response assessment. Recently, promising results were achieved in management of cancer patients by extracting mineable high-dimensional data from medical images, supporting clinicians in decision-making process in the new era of target therapy and personalized medicine. Radiomics could provide quantitative data, extracted from medical images, that could reflect microenvironmental tumor heterogeneity, which might be a useful information for treatment tailoring. Thus, it could be helpful to overcome the main limitations of traditional tumor biopsy, often affected by bias in tumor sampling, lack of repeatability and possible procedure complications. This quantitative approach has been widely investigated as a non-invasive and an objective imaging biomarker in cancer patients; however, it is not applied as a clinical routine due to several limitations related to lack of standardization and validation of images acquisition protocols, features segmentation, extraction, processing, and data analysis. This field is in continuous evolution in each type of cancer, and results support the idea that in the future Radiomics might be a reliable application in oncologic imaging. The first part of this review aimed to describe some radiomic technical principles and clinical applications to gastrointestinal oncologic imaging (CT and MRI) with a focus on diagnosis, prediction prognosis, and assessment of response to therapy.
Open AccessRadiomics in Oncology, Part 1: Technical Principles and Gastrointestinal Application in CT and MRI
Radiomics has been playing a pivotal role in oncological translational imaging, particularly in cancer diagnosis, prediction prognosis, and therapy response assessment. Recently, promising results were achieved in management of cancer patients by extracting mineable high-dimensional data from medical images, supporting clinicians in decision-making process in the new era of target therapy and personalized medicine. Radiomics could provide quantitative data, extracted from medical images, that could reflect microenvironmental tumor heterogeneity, which might be a useful information for treatment tailoring. Thus, it could be helpful to overcome the main limitations of traditional tumor biopsy, often affected by bias in tumor sampling, lack of repeatability and possible procedure complications. This quantitative approach has been widely investigated as a non-invasive and an objective imaging biomarker in cancer patients; however, it is not applied as a clinical routine due to several limitations related to lack of standardization and validation of images acquisition protocols, features segmentation, extraction, processing, and data analysis. This field is in continuous evolution in each type of cancer, and results support the idea that in the future Radiomics might be a reliable application in oncologic imaging. The first part of this review aimed to describe some radiomic technical principles and clinical applications to gastrointestinal oncologic imaging (CT and MRI) with a focus on diagnosis, prediction prognosis, and assessment of response to therapy.
- Open Access
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1)
Magnetic Resonance of Rectal Cancer Response to Therapy: An Image Quality Comparison between 3.0 and 1.5 Tesla
Purpose. To evaluate signal intensity (SI) differences between 3.0 T and 1.5 T on T2‐weighted (T2w), diffusion‐weighted imaging (DWI), and apparent diffusion coefficient (ADC) in rectal cancer pre‐, during, and postneoadjuvant chemoradiotherapy (CRT). Materials and Methods. 22 patients with locally advanced rectal cancer were prospectively enrolled. All patients underwent T2w, DWI, and ADC pre‐, during, and post‐CRT on both 3.0 T MRI and 1.5 T MRI. A radiologist drew regions of interest (ROIs) of the tumor and obturator internus muscle on the selected slice to evaluate SI and relative SI (rSI). Additionally, a subanalysis evaluating the SI before and after‐CRT (∆SI pre‐post) in complete responder patients (CR) and nonresponder patients (NR) on T2w, DWI, and ADC was performed. Results. Significant differences were observed for T2w and DWI on 3.0 T MRI compared to 1.5 T MRI pre‐, during, and post‐CRT (all P < 0.001), whereas no significant differences were reported for ADC among all controls (all P > 0.05). rSI showed no significant differences in all the examinations for all sequences (all P > 0.05). ∆SI showed significant differences between 3.0 T and 1.5 T MRI for DWI‐∆SI in CR and NR (188.39 ± 166.90 vs. 30.45 ± 21.73 and 169.70 ± 121.87 vs. 22.00 ± 31.29, respectively, all P 0.02) and ADC‐∆SI for CR (−0.58 ± 0.27 vs. −0.21 ± 0.24P value 0.02), while no significant differences were observed for ADC‐∆SI in NR and both CR and NR for T2w‐∆SI. Conclusion. T2w‐SI and DWI‐SI showed significant differences for 3.0 T compared to 1.5 T in all three controls, while ADCSI showed no significant differences in all three controls on both field strengths. rSI was comparable for 3.0 T and 1.5 T MRI in rectal cancer patients; therefore, rectal cancer patients can be assessed both at 3.0 T MRI and 1.5 T MRI. However, a significant DWI‐∆SI and ADC‐∆SI on 3.0 T in CR might be interpreted as a better visual assessment in discriminating response to therapy compared to 1.5 T. Further investigations should be performed to confirm future possible clinical application.
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1)
Open AccessMagnetic Resonance of Rectal Cancer Response to Therapy: An Image Quality Comparison between 3.0 and 1.5 Tesla
Purpose. To evaluate signal intensity (SI) differences between 3.0 T and 1.5 T on T2‐weighted (T2w), diffusion‐weighted imaging (DWI), and apparent diffusion coefficient (ADC) in rectal cancer pre‐, during, and postneoadjuvant chemoradiotherapy (CRT). Materials and Methods. 22 patients with locally advanced rectal cancer were prospectively enrolled. All patients underwent T2w, DWI, and ADC pre‐, during, and post‐CRT on both 3.0 T MRI and 1.5 T MRI. A radiologist drew regions of interest (ROIs) of the tumor and obturator internus muscle on the selected slice to evaluate SI and relative SI (rSI). Additionally, a subanalysis evaluating the SI before and after‐CRT (∆SI pre‐post) in complete responder patients (CR) and nonresponder patients (NR) on T2w, DWI, and ADC was performed. Results. Significant differences were observed for T2w and DWI on 3.0 T MRI compared to 1.5 T MRI pre‐, during, and post‐CRT (all P < 0.001), whereas no significant differences were reported for ADC among all controls (all P > 0.05). rSI showed no significant differences in all the examinations for all sequences (all P > 0.05). ∆SI showed significant differences between 3.0 T and 1.5 T MRI for DWI‐∆SI in CR and NR (188.39 ± 166.90 vs. 30.45 ± 21.73 and 169.70 ± 121.87 vs. 22.00 ± 31.29, respectively, all P 0.02) and ADC‐∆SI for CR (−0.58 ± 0.27 vs. −0.21 ± 0.24P value 0.02), while no significant differences were observed for ADC‐∆SI in NR and both CR and NR for T2w‐∆SI. Conclusion. T2w‐SI and DWI‐SI showed significant differences for 3.0 T compared to 1.5 T in all three controls, while ADCSI showed no significant differences in all three controls on both field strengths. rSI was comparable for 3.0 T and 1.5 T MRI in rectal cancer patients; therefore, rectal cancer patients can be assessed both at 3.0 T MRI and 1.5 T MRI. However, a significant DWI‐∆SI and ADC‐∆SI on 3.0 T in CR might be interpreted as a better visual assessment in discriminating response to therapy compared to 1.5 T. Further investigations should be performed to confirm future possible clinical application.